Seeking Alpha

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual ...

– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients – – 63% ...
Seeking Alpha

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

WALTHAM, Mass., March 28, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced ...
Benzinga.com

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 ...
The American Journal of Managed Care

FDA Approves CytoCell CDx for Revumenib in KMT2A-Mutant Acute Leukemia

The CytoCell KMT2A Breakapart FISH Probe Kit PDx is approved as a companion diagnostic for revumenib in KMT2A translocated acute leukemia. Revumenib showed a 21.2% complete remission rate in ...
The American Journal of Managed Care

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
Nasdaq

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

– New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile – – 64% ORR (62/97) in expanded dataset of patients with R/R KMT2Ar acute leukemia in ...
Cure Today

Revuforj Continues to Elicit Meaningful Responses in Some With Acute Leukemia

Revuforj shows a 63.9% overall response rate in relapsed/refractory KMT2Ar acute leukemia, with significant MRD negativity and HSCT progression rates. The AUGMENT-101 trial reports a median duration ...
Oklahoma's News

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced ...
Cure Today

FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset

Revuforj is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. The AUGMENT-101 trial showed a 21.2% complete remission rate with a median ...
The Victoria Advocate

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Positive pivotal data from the AUGMENT-101 trial in this population with revumenib as a monotherapy were recently reported. The Company expects to file a supplemental NDA filing for revumenib in R/R ...
WIVB-TV

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

The AUGMENT-101 Phase 2 safety population included 84 adult and pediatric patients with R/R mNPM1 AML. Detailed results from this safety population were previously published in the journal Blood and ...